Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Androgen receptor inhibitor (ARSI)
Darolutamide
Nubeqa · DARO
Next-generation androgen receptor inhibitor for prostate cancer; not intrinsically nephrotoxic, but systemic exposure rises in severe renal impairment, prompting dose consideration.
Mildrecent · approved 2019
Nonmetastatic castration-resistant prostate cancer (nmCRPC)Metastatic hormone-sensitive prostate cancer (mHSPC), in combination with docetaxel and androgen-deprivation therapy
Signature kidney injury
Electrolyte Wasting
No characteristic intrinsic nephrotoxicity. In ARAMIS, rates of adverse events including hypertension were similar to placebo. Renal-relevant findings are pharmacokinetic (increased exposure in severe renal impairment); intrinsic renal injury incidence not meaningfully quantified.
Source: Fizazi et al., NEJM 2019 (ARAMIS; AE profile similar to placebo)
Mechanism of kidney injury
Darolutamide is not an established direct nephrotoxin. Its renal relevance is pharmacokinetic: it is metabolized (oxidation and glucuronidation) and excreted in urine and feces, and systemic exposure increases in patients with severe renal impairment, so accumulation — not tubular or glomerular injury — is the concern. As an AR-pathway inhibitor (ARSI class), it can be associated with class-level cardiometabolic and, uncommonly, electrolyte/blood-pressure effects, but it showed no excess hypertension versus placebo in its pivotal trial. Any prerenal physiology relates to general illness/volume status rather than a specific drug lesion.
Clinical presentation
Generally no renal-specific presentation. Clinically, the issue is increased darolutamide exposure (and potential for exposure-related adverse effects) in patients with moderate-to-severe renal impairment, rather than a recognizable nephrotoxic syndrome. Mild electrolyte or blood-pressure changes are uncommon and class-level.
Onset
Not applicable for intrinsic injury; exposure differences in renal impairment are present from initiation and steady state (reached in ~2 days).
Reversibility
Reversible
Anticancer mechanism
Structurally distinct second-generation androgen receptor (AR) signaling inhibitor that competitively antagonizes the AR, blocks AR nuclear translocation and AR-mediated transcription, and has low blood-brain barrier penetration (reducing CNS/seizure effects); it suppresses AR-driven prostate cancer growth.
Management
No renal-specific treatment is needed for the drug itself. In severe renal impairment, consider dose adaptation at treatment initiation given increased exposure, and monitor for exposure-related adverse effects. Manage incidental electrolyte/blood-pressure changes supportively.
Risk factors
- Severe renal impairment (increased exposure)
- Concurrent moderate hepatic impairment (also increases exposure)
- Co-administration affecting BCRP substrates / shared metabolic pathways
- General frailty/volume depletion in advanced prostate cancer
Prevention
- Recognize that exposure rises in severe renal impairment; consider a reduced starting dose in severe renal (and severe hepatic) impairment per labeling
- Review concomitant medications for interaction potential (e.g., BCRP substrates)
- Routine renal-specific prophylaxis not otherwise required
Note · Teaching emphasis: this is a pharmacokinetic (exposure) consideration, not nephrotoxicity. Darolutamide's low CNS penetration distinguishes it within the ARSI class; its renal story is about dose adaptation in severe impairment.
Clinical depth
Renal dose adjustment
Per pharmacokinetic data and labeling, a reduced starting dose (e.g., 300 mg twice daily) should be considered in severe renal impairment (and in moderate hepatic impairment) because systemic exposure is increased; standard 600 mg twice daily otherwise.
Dialyzability & ESKD dosing
Dialyzability not formally established; darolutamide is substantially protein-bound and hepatically metabolized, so dialysis is unlikely to be a primary management consideration. Use clinical judgment and labeling in dialysis patients.
Differential diagnosis
AKI or electrolyte disturbance in a darolutamide-treated patient should prompt evaluation for dehydration, obstruction from prostate cancer, contrast/other nephrotoxins, or concomitant therapy — rather than attribution to a direct darolutamide tubular effect.
Monitoring
- Renal (and hepatic) function to inform starting dose
- Blood pressure (class-level monitoring)
- For exposure-related tolerability in severe renal impairment
- Concomitant BCRP-substrate drugs
Key trials & series
- ARAMIS (Fizazi et al., NEJM 2019): darolutamide prolonged metastasis-free survival in nmCRPC with an adverse-event profile similar to placebo (no excess hypertension, seizures, or falls)
- Zurth et al. (Clin Pharmacokinet 2021): dedicated PK study showing increased exposure in severe renal and moderate hepatic impairment, recommending dose-adaptation consideration
Clinical pearls
- Not a nephrotoxin — the renal angle is pharmacokinetic: exposure rises in severe renal impairment, so consider a reduced starting dose.
- ARAMIS showed an AE profile similar to placebo, including no excess hypertension.
- Low blood-brain-barrier penetration limits CNS/seizure effects, a class-distinguishing feature.
- Watch BCRP-substrate interactions; little CYP/P-gp interaction otherwise.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Injury signatures
Electrolyte WastingPrerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of androgen receptor inhibitor (arsi)s.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT, hypertension, fluid retention
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
- Bone loss, fatigue, hot flashes
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis (abiraterone)
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
PMIDClinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.Zurth C et al. · Clin Pharmacokinet 2021 · PMID 34866168Primary PK evidence that darolutamide exposure increases in severe renal (and moderate hepatic) impairment, with the recommendation that dose adaptation at initiation be considered.PMIDClinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.Podgorsek E et al. · Clin Pharmacokinet 2023 · PMID 37458966Review confirming metabolism/excretion routes and that dose reduction is required in moderate-to-severe renal or severe hepatic impairment; details low brain distribution and BCRP-substrate interaction.LandmarkDarolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.Fizazi K et al. · N Engl J Med 2019 · PMID 30763142ARAMIS pivotal trial documenting efficacy and a placebo-like adverse-event profile (no excess hypertension/seizures), supporting the absence of characteristic nephrotoxicity.